Dividends & Buybacks ·
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in…
NVONovo Nordisk A S
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in shares during a 12-month period starting February 4, 2026. Under the specific tranche initiated on May 6, 2026, the company intends to repurchase B shares up to DKK 11,200,000,010.45 through February 1, 2027. Between July 13 and July 17, 2026, the company executed five transactions totaling 975,000 B shares for a value of DKK 322,693,858. As of July 17, 2026, total repurchases under the programme since February 4 amount to 24,959,179 B shares at an average price of DKK 274.58. The company is a global healthcare company specializing in diabetes and chronic disease treatments.